Sage Therapeutics (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Bank of America started coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report released on Tuesday. The brokerage issued an underperform rating and a $5.00 target price on the ...

US Bancorp DE raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 22.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC.

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against other best small-cap growth stocks to buy now. On November 4, 2024, Nick Sheridan ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the ...